A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting

Trial Profile

A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 26 May 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Cabazitaxel; Docetaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma; Medivation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 May 2017 Status changed from active, no longer recruiting to discontinued due to feasibility reasons.
    • 20 Mar 2017 Planned End Date changed from 1 Nov 2018 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top